
Bridget E. Bunner
Examiner (ID: 17180)
| Most Active Art Unit | 1647 |
| Art Unit(s) | 1647, 1644 |
| Total Applications | 1462 |
| Issued Applications | 724 |
| Pending Applications | 157 |
| Abandoned Applications | 602 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 11827693
[patent_doc_number] => 09724422
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2017-08-08
[patent_title] => 'Human lactoferrin derived peptide for use as an antigen masking agent'
[patent_app_type] => utility
[patent_app_number] => 13/988829
[patent_app_country] => US
[patent_app_date] => 2010-11-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 6086
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13988829
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/988829 | Human lactoferrin derived peptide for use as an antigen masking agent | Nov 25, 2010 | Issued |
Array
(
[id] => 7783876
[patent_doc_number] => 20120045432
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2012-02-23
[patent_title] => 'B LYMPHOCYTE STIMULATOR ASSAYS'
[patent_app_type] => utility
[patent_app_number] => 12/952091
[patent_app_country] => US
[patent_app_date] => 2010-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 199557
[patent_no_of_claims] => 57
[patent_no_of_ind_claims] => 25
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0045/20120045432.pdf
[firstpage_image] =>[orig_patent_app_number] => 12952091
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/952091 | B LYMPHOCYTE STIMULATOR ASSAYS | Nov 21, 2010 | Abandoned |
Array
(
[id] => 7783876
[patent_doc_number] => 20120045432
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2012-02-23
[patent_title] => 'B LYMPHOCYTE STIMULATOR ASSAYS'
[patent_app_type] => utility
[patent_app_number] => 12/952091
[patent_app_country] => US
[patent_app_date] => 2010-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 199557
[patent_no_of_claims] => 57
[patent_no_of_ind_claims] => 25
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0045/20120045432.pdf
[firstpage_image] =>[orig_patent_app_number] => 12952091
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/952091 | B LYMPHOCYTE STIMULATOR ASSAYS | Nov 21, 2010 | Abandoned |
Array
(
[id] => 8074019
[patent_doc_number] => 20110240012
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-10-06
[patent_title] => 'RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS'
[patent_app_type] => utility
[patent_app_number] => 12/945622
[patent_app_country] => US
[patent_app_date] => 2010-11-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10007
[patent_no_of_claims] => 36
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0240/20110240012.pdf
[firstpage_image] =>[orig_patent_app_number] => 12945622
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/945622 | RECOMBINANT HUMAN CC10 AND COMPOSITIONS THEREOF FOR USE IN THE TREATMENT OF NASAL RHINITIS | Nov 11, 2010 | Abandoned |
Array
(
[id] => 10143339
[patent_doc_number] => 09176147
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-11-03
[patent_title] => 'Detection of B-cell activating factor as a biomarker for antibody mediated rejection in transplant recipients'
[patent_app_type] => utility
[patent_app_number] => 13/501671
[patent_app_country] => US
[patent_app_date] => 2010-10-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 10
[patent_no_of_words] => 12217
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 88
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13501671
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/501671 | Detection of B-cell activating factor as a biomarker for antibody mediated rejection in transplant recipients | Oct 24, 2010 | Issued |
Array
(
[id] => 9823345
[patent_doc_number] => 08932829
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-01-13
[patent_title] => 'Recombinant alpha-fetoprotein and compositions thereof'
[patent_app_type] => utility
[patent_app_number] => 12/925513
[patent_app_country] => US
[patent_app_date] => 2010-10-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 28
[patent_figures_cnt] => 28
[patent_no_of_words] => 11992
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12925513
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/925513 | Recombinant alpha-fetoprotein and compositions thereof | Oct 21, 2010 | Issued |
Array
(
[id] => 10856952
[patent_doc_number] => 08883145
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-11-11
[patent_title] => 'Methods of treatment with DLL4 antagonists and an anti-hypertensive agent'
[patent_app_type] => utility
[patent_app_number] => 13/501944
[patent_app_country] => US
[patent_app_date] => 2010-10-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 13624
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13501944
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/501944 | Methods of treatment with DLL4 antagonists and an anti-hypertensive agent | Oct 17, 2010 | Issued |
Array
(
[id] => 10169370
[patent_doc_number] => 09200071
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-12-01
[patent_title] => 'Methods of treating cancer using Notch1 and Notch3 antagonists'
[patent_app_type] => utility
[patent_app_number] => 13/498560
[patent_app_country] => US
[patent_app_date] => 2010-09-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 25
[patent_figures_cnt] => 41
[patent_no_of_words] => 15807
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 42
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13498560
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/498560 | Methods of treating cancer using Notch1 and Notch3 antagonists | Sep 28, 2010 | Issued |
Array
(
[id] => 5959529
[patent_doc_number] => 20110183916
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-07-28
[patent_title] => 'Apo-2 Ligand'
[patent_app_type] => utility
[patent_app_number] => 12/924163
[patent_app_country] => US
[patent_app_date] => 2010-09-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 27161
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0183/20110183916.pdf
[firstpage_image] =>[orig_patent_app_number] => 12924163
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/924163 | Apo-2 Ligand | Sep 21, 2010 | Abandoned |
Array
(
[id] => 8994530
[patent_doc_number] => 08518412
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-08-27
[patent_title] => 'Partial peptide of lacritin'
[patent_app_type] => utility
[patent_app_number] => 13/496437
[patent_app_country] => US
[patent_app_date] => 2010-09-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 10357
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13496437
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/496437 | Partial peptide of lacritin | Sep 15, 2010 | Issued |
Array
(
[id] => 6024918
[patent_doc_number] => 20110053244
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-03-03
[patent_title] => 'NOVEL PROTEIN DELIVERY SYSTEM TO GENERATE INDUCED PLURIPOTENT STEM (iPS) CELLS OR TISSUE-SPECIFIC CELLS'
[patent_app_type] => utility
[patent_app_number] => 12/870782
[patent_app_country] => US
[patent_app_date] => 2010-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 17
[patent_no_of_words] => 7013
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0053/20110053244.pdf
[firstpage_image] =>[orig_patent_app_number] => 12870782
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/870782 | Protein delivery system to generate pluripotent stem (iPS) cells or tissue specific cells | Aug 26, 2010 | Issued |
Array
(
[id] => 7776309
[patent_doc_number] => 20120039890
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2012-02-16
[patent_title] => 'METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA'
[patent_app_type] => utility
[patent_app_number] => 12/870548
[patent_app_country] => US
[patent_app_date] => 2010-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 162853
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0039/20120039890.pdf
[firstpage_image] =>[orig_patent_app_number] => 12870548
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/870548 | Methods of treatment using antibodies to Neutrokine-alpha | Aug 26, 2010 | Issued |
Array
(
[id] => 7776309
[patent_doc_number] => 20120039890
[patent_country] => US
[patent_kind] => A9
[patent_issue_date] => 2012-02-16
[patent_title] => 'METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA'
[patent_app_type] => utility
[patent_app_number] => 12/870548
[patent_app_country] => US
[patent_app_date] => 2010-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 23
[patent_figures_cnt] => 23
[patent_no_of_words] => 162853
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A9/0039/20120039890.pdf
[firstpage_image] =>[orig_patent_app_number] => 12870548
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/870548 | Methods of treatment using antibodies to Neutrokine-alpha | Aug 26, 2010 | Issued |
Array
(
[id] => 6343342
[patent_doc_number] => 20100330073
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-12-30
[patent_title] => 'METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA'
[patent_app_type] => utility
[patent_app_number] => 12/870394
[patent_app_country] => US
[patent_app_date] => 2010-08-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 22
[patent_figures_cnt] => 22
[patent_no_of_words] => 162891
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0330/20100330073.pdf
[firstpage_image] =>[orig_patent_app_number] => 12870394
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/870394 | METHODS OF TREATMENT USING ANTIBODIES TO NEUTROKINE-ALPHA | Aug 26, 2010 | Abandoned |
Array
(
[id] => 8209016
[patent_doc_number] => 20120128682
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-24
[patent_title] => 'APOLIPOPROTEIN L- I VARIANTS AND THEIR USE'
[patent_app_type] => utility
[patent_app_number] => 13/388645
[patent_app_country] => US
[patent_app_date] => 2010-08-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 3686
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0128/20120128682.pdf
[firstpage_image] =>[orig_patent_app_number] => 13388645
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/388645 | APOLIPOPROTEIN L- I VARIANTS AND THEIR USE | Aug 17, 2010 | Abandoned |
Array
(
[id] => 8312669
[patent_doc_number] => 20120189690
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-07-26
[patent_title] => 'Liposomes covered with the Extracellular Domain of the APO2L/Trail Protein'
[patent_app_type] => utility
[patent_app_number] => 13/391582
[patent_app_country] => US
[patent_app_date] => 2010-08-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 21
[patent_figures_cnt] => 21
[patent_no_of_words] => 12733
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13391582
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/391582 | Liposomes covered with the Extracellular Domain of the APO2L/Trail Protein | Aug 11, 2010 | Abandoned |
Array
(
[id] => 8689948
[patent_doc_number] => 08389475
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-03-05
[patent_title] => 'Relaxin analogs'
[patent_app_type] => utility
[patent_app_number] => 12/852373
[patent_app_country] => US
[patent_app_date] => 2010-08-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 13787
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12852373
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/852373 | Relaxin analogs | Aug 5, 2010 | Issued |
Array
(
[id] => 6007083
[patent_doc_number] => 20110059114
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-03-10
[patent_title] => 'Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells'
[patent_app_type] => utility
[patent_app_number] => 12/851482
[patent_app_country] => US
[patent_app_date] => 2010-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 13125
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0059/20110059114.pdf
[firstpage_image] =>[orig_patent_app_number] => 12851482
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/851482 | Compositions and Methods for the Treatment of Radioresistant Glioma Stem Cells | Aug 4, 2010 | Abandoned |
Array
(
[id] => 8220811
[patent_doc_number] => 20120135011
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-31
[patent_title] => 'Method for in vivo expansion of T regulatory cells'
[patent_app_type] => utility
[patent_app_number] => 13/388722
[patent_app_country] => US
[patent_app_date] => 2010-08-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 20609
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 8
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13388722
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/388722 | Method for in vivo expansion of T regulatory cells | Aug 2, 2010 | Issued |
Array
(
[id] => 8209975
[patent_doc_number] => 20120129189
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-05-24
[patent_title] => 'Methods of Controlling Cell Proliferation'
[patent_app_type] => utility
[patent_app_number] => 13/383819
[patent_app_country] => US
[patent_app_date] => 2010-07-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 29052
[patent_no_of_claims] => 26
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0129/20120129189.pdf
[firstpage_image] =>[orig_patent_app_number] => 13383819
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/383819 | Methods of Controlling Cell Proliferation | Jul 15, 2010 | Abandoned |